These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6539935)

  • 1. The relationship between haloperidol blood levels and clinical responses.
    Itoh H; Yagi G; Fujii Y; Iwamura K; Ichikawa K
    Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(2):285-92. PubMed ID: 6539935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
    Volavka J; Cooper TB; Meisner M; Bitter I; Czobor P; Jaeger J
    Psychopharmacol Bull; 1990; 26(1):13-7. PubMed ID: 2371368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of plasma haloperidol concentrations by radioreceptor assay in schizophrenia: clinical utility.
    Santos JL; Ramos JA; Prieto P; Almoguera I; Vazquez C; Rubio ME; Cabranes JA
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(6):917-25. PubMed ID: 2813809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
    Magliozzi JR; Hollister LE; Arnold KV; Earle GM
    Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays.
    Smith RC; Baumgartner R; Misra CH; Mauldin M; Shvartsburd A; Ho BT; DeJohn C
    Arch Gen Psychiatry; 1984 Nov; 41(11):1044-9. PubMed ID: 6497566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors affecting the clinical response to haloperidol therapy in schizophrenia.
    Bareggi SR; Mauri M; Cavallaro R; Regazzetti MG; Moro AR
    Clin Neuropharmacol; 1990; 13 Suppl 1():S29-34. PubMed ID: 2379182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia.
    Balant-Gorgia AE; Eisele R; Balant L; Garrone G
    Eur Arch Psychiatry Neurol Sci; 1984; 234(1):1-4. PubMed ID: 6489392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia.
    Santos JL; Cabranes JA; Vazquez C; Fuentenebro F; Almoguera I; Ramos JA
    Biol Psychiatry; 1989 Aug; 26(4):381-8. PubMed ID: 2669981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship of haloperidol concentrations to therapeutic response.
    Perry PJ; Pfohl BM; Kelly MW
    J Clin Psychopharmacol; 1988 Feb; 8(1):38-43. PubMed ID: 3350997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis.
    Stevens A; Stevens I; Mahal A; Gaertner HJ
    Pharmacopsychiatry; 1992 Nov; 25(6):273-7. PubMed ID: 1494594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute and subchronic effects of low-dose bromocriptine in haloperidol-treated schizophrenics.
    Gattaz WF; Rost W; Hübner CK; Bauer K
    Biol Psychiatry; 1989 Feb; 25(3):247-55. PubMed ID: 2643996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suspension therapy in acute schizophrenia. Clinical and neuroendocrine/biochemical effects of abrupt discontinuation of neuroleptic medication.
    Kuhs H; Folkerts H
    Neuropsychobiology; 1995; 31(3):135-45. PubMed ID: 7609862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haloperidol and reduced haloperidol serum levels: correlation with psychopathology in acute schizophrenia.
    Stevens A; Mahal A; Gaertner HJ
    Pharmacopsychiatry; 1992 Sep; 25(5):218-23. PubMed ID: 1409866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RBC and plasma levels of haloperidol and clinical response in schizophrenia.
    Smith RC; Vroulis G; Shvartsburd A; Allen R; Lewis N; Schoolar JC; Chojnacki M; Johnson R
    Am J Psychiatry; 1982 Aug; 139(8):1054-6. PubMed ID: 7091432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total and free plasma neuroleptic levels in schizophrenic patients.
    Tang SW; Glaister J; Davidson L; Toth R; Jeffries JJ; Seeman P
    Psychiatry Res; 1984 Dec; 13(4):285-93. PubMed ID: 6596586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haloperidol plasma levels and dose optimization.
    Coryell W; Miller DD; Perry PJ
    Am J Psychiatry; 1998 Jan; 155(1):48-53. PubMed ID: 9433338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients.
    Moulin MA; Davy JP; Debruyne D; Andersson JC; Bigot MC; Camsonne R; Poilpré E
    Psychopharmacology (Berl); 1982; 76(4):346-50. PubMed ID: 6812109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.
    Arvanitis LA; Miller BG
    Biol Psychiatry; 1997 Aug; 42(4):233-46. PubMed ID: 9270900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia.
    Kelly MW; Perry PJ; Coryell WH; Miller DD; Arndt SV
    Psychopharmacology (Berl); 1990; 102(4):514-20. PubMed ID: 2096408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
    Jann MW; Crabtree BL; Pitts WM; Lam YW; Carter JG
    Neuropsychobiology; 1997; 36(1):32-6. PubMed ID: 9211442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.